Fig. 4
Immunomodulation of cAM-MSCs on Days 4 and 8 in vitro. (A) Schematic overview of the use co-culture for immunemodulation. (B) Representative phase-contrast image of CTL (PBMCs), PBMCs were treated with concanavalin A (conA; 5 μm/ml), conA combined with MSCs (1 × 105cells), conA combined with pimecrolimus (Pime; 100 ng/ml) on Days 4 (upper) and 8 (bottom). Scale bars, 200 μm. (C) On Day 4 of the MLR assay, lymphocytes were quantified in triplicate using absorbance at 540 nm. mean ± SD; ** p < 0.01, *** p < 0.001. (D) On Day 8 of the MLR assay, lymphocytes were quantified in triplicate using absorbance at 540 nm, mean ± SD; *** p < 0.001